Study | Type of surgery | Patients (GDFT), n | Patients (control), n | Risk | Age, years | GDFTdyn goals | Other goals | Monitoring devices | Interventions |
---|---|---|---|---|---|---|---|---|---|
Benes J 2010 [13] | Major abdominal | 60 | 60 | High | > 18 | SVV < 10% | CI 2.5–4 L/min/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Broch O 2016 [14] | Major abdominal | 39 | 40 | High | > 18 | PPV < 10%a | CI > 2.5 L/min/m2 | Nexfinb | Fluid inotropes vasopressors |
Buettner M 2008 [15] | Major abdominal | 40 | 40 | High | > 18 | SPV < 10% | – | PiCCOplus | Fluid vasopressor |
Cesur S 2018 [16] | Abdominal | 35 | 35 | Moderate | > 18 | PVI < 13% | – | Masimo Radical 7b | Fluid vasopressors |
Colantonio L 2015 [17] | Major abdominal | 38 | 42 | High | > 18 | SVV < 15% | SVI > 35 mL/min/m2 CI > 2.5 L/min/m2 | FloTrac/Vigileo | Fluid inotropes |
Correa-Gallego C 2015 [18] | Major abdominal | 69 | 66 | High | NR | SVV < 15% | CO > 4 L/min CI > 2 L/min/m2 | FloTrac | Fluid |
Demirel İ 2018 [19] | Abdominal | 30 | 30 | Moderate | > 18 | PVI < 14% | – | Masimo Co.b | Fluid vasopressors |
Elgendy MA 2017 [20] | High risk | 43 | 43 | High | NR | SVV < 12% | CI > 2.5 L/min/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Fellahi JL 2015 [21] | Cardiac | 48 | 44 | High | > 18 | SVV ≤11% | CI > 2.4 L/min/m2 | Endotracheal cardiac output monitor | Fluid inotropes |
Forget P 2010 [22] | Abdominal | 41 | 41 | Moderate | > 18 | PVI < 13% | – | Masimo Co.b | Fluid vasopressors |
Funk DJ 2015 [23] | Major vascular | 20 | 20 | High | > 18 | SVV < 13% | CI > 2.2 L/min/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Goepfert MS 2013 [24] | Cardiac | 50 | 50 | High | > 18 | SVV < 10% | CI > 2 L/min/m2 | PiCCOplus | Fluid inotropes vasopressors |
Hand WR 2016 [25] | Head and neck | 47 | 47 | Moderate | NR | SVV < 13% | CI > 3 L/min/m2 SVR > 800 dynes/s/cm5/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Harten J 2008 [26] | Emergency abdominal | 14 | 15 | High | > 50 | PPV < 10% | – | Lidco plus | Fluid |
Kapoor PM 2008 [27] | Cardiac | 13 | 14 | High | NR | SVV < 10%a | CI 2.5–4.2 L/min/m2 SVI 30-65 mL/beat/m2 SVRI: 1500–2500 dynes/s/cm5/m2 DO2 450–600 mL/min/m2 ScVO2 > 70% | FloTrac/Vigileo | Fluid inotropes vasoactives |
Kapoor PM 2016 [28] | Cardiac | 60 | 60 | High | NR | SVV < 10%a | CI 2.5–4.2 L/min/m2 SVI 30–65 mL/beat/m2 SVRI 1500–2500 dynes/s/cm5/m2 DO2 450–600 mL/min/m2 ScVO2 > 70% Hct > 30% ScVO2 > 70% | FloTrac/Vigileo | Fluid inotropes vasodilators |
Kim HJ 2018 [29] | Head and neck | 31 | 31 | Moderate | 20–80 | SVV < 12% | CI > 2.5 L/min/m2 | FloTrac/Vigileo | Fluid inotropes vasodilators |
Kumar L 2016 [30] | Major abdominal | 30 | 30 | High | > 18 | SVV < 10% | CI ≥2.5 L/min/m2 O2ER ≤ 27% | FloTrac/Vigileo | Fluid inotropes vasopressors |
Lai CW 2015 [31] | Major abdominal | 109 | 111 | High | NR | SVV < 10% | – | LiDCOrapid | Fluid |
Liang M 2017 [32] | Urologic | 30 | 30 | High | 60–80 | SVV 8%–13% | DO2I ≥ 500 mL/min/m2 | FloTrac/Vigileo | Fluid inotropes |
Lopes MR 2007 [33] | High risk | 17 | 16 | High | > 18 | PPV < 10% | – | IBPplus | Fluid |
Luo J 2017 [34] | Craniotomy | 73 | 72 | High | > 18 | SVV < 15% | CI > 2.5 L/min/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Mayer J 2010 [35] | Major abdominal | 30 | 30 | High | > 18 | SVV < 12% | CI > 2.5 L/min/m2 SVI > 35 mL/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Peng K 2014 [36] | Major orthopedic | 40 | 40 | High | > 18 | SVV < 10%/14% | – | FloTrac/Vigileo | Fluid vasopressors |
Pösö T 2014 [37] | Abdominal | 30 | 20 | Moderate | NR | SVV < 12% | CI ≥2.0 L/min/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Ramsingh DS 2013 [38] | Major abdominal | 18 | 20 | High | > 18 | SVV < 12% | – | FloTrac/Vigileo | Fluid |
Salzwedel C 2013 [39] | Major abdominal | 79 | 81 | High | NR | PPV < 10% | CI > 2.5 L/min/m2 | ProAQT | Fluid inotropes vasopressors |
Scheeren TW 2013 [40] | High risk | 26 | 26 | High | > 18 | SVV < 10% | SV rise > 10% | FloTrac/Vigileo | Fluid |
Stens J 2015 [41] | Abdominal | 13 | 18 | Moderate | > 18 | PPV < 12% | CI > 2.5 L/min/m2 | Nexfinb | Fluid inotropes vasopressors |
Sundaram SC 2016 [42] | Intracranial tumor | 30 | 30 | High | 20–80 | PPV < 13% | – | Phillips Intellivue MP50 | Fluid vasopressors |
Weinberg L 2017 [43] | Major abdominal | 26 | 26 | High | > 18 | SVV < 20% | CI > 2.0 L/min/m2 PaO2 > 100 mmHg Hb > 8 g/dL T > 36 °C | FloTrac/Vigileo | Fluid inotropes vasopressors |
Wu J 2017 [44] | Intracranial tumor | 33 | 30 | High | NR | SVV < 12% | CI > 2.5 L/min/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Xu H 2017 [45] | Thoracic | 84 | 84 | Moderate | 18–60 | SVV 10– 13% | CI > 2.5 L/min/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Yu Y 2014 [46] | Abdominal | 15 | 15 | Moderate | 20–65 | PVI < 13% | – | Masimo Radical 7b | Fluid vasopressors |
Zhang J 2013 [47] | Thoracic | 30 | 30 | Moderate | 18–60 | SVV 9– 11% | CI > 2.5 L/min/m2 | FloTrac/Vigileo | Fluid inotropes |
Zheng H 2013 [48] | Major abdominal | 30 | 30 | High | 60–80 | SVV < 12% | CI > 2.5 L/min/m2 SVI > 35 mL/m2 | FloTrac/Vigileo | Fluid inotropes vasopressors |
Zheng LS 2016 [49] | Major abdominal | 39 | 37 | High | 65–90 | SVV < 12% | CI > 2.5 L/min/m2 | FloTrac/Vigileo | Fluid vasopressors |